HealthQuill Valneva SE
Pfizer Inc. and France-based Valneva SE's investigational vaccine has shown 70% efficacy in preventing Lyme disease in individuals aged five and above.
Drugs Medical Pharma

Pfizer, Valneva’s experimental Lyme disease vaccine shows 70% efficacy

HQ Team March 25, 2026: Pfizer Inc. and France-based Valneva SE‘s investigational vaccine has shown 70% efficacy in preventing Lyme disease in individuals.

Read More
Valneva SE, a French vaccine maker, has got USFDA approval for its chikungunya vaccine, Ixchiq, to treat individuals older than 18 years of age and who are at increased risk of exposure to the disease.
Drugs Health Pharma

Valneva’s chikungunya jab gets FDA nod, first such for disease

HQ Team November 10, 2023: Valneva SE, a French vaccine maker, has got USFDA approval for its chikungunya vaccine, Ixchiq, to treat individuals.

Read More
Valneva SE, a French vaccine maker, announced that its last-stage trials for its single-shot chikungunya registered a 98.9% vaccination success rate.
Drugs Medical Pharma

France’s Valneva says trial vaccine for chikungunya post 98.9% rate

HQ Team June 13, 2023: Valneva SE, a French vaccine maker, announced that its last-stage trials for its single-shot chikungunya registered a 98.9%.

Read More